A Phase IIa, Open-Label, Single- Center Study to Assess the Activity of Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Oshadi D (Primary) ; Oshadi R (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Oshadi Drug Administration
- 21 Apr 2015 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.
- 21 Apr 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.
- 02 Sep 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.